Laura Prendergast
Stock Analyst at Raymond James
(0.02)
# 4,269
Out of 4,974 analysts
7
Total ratings
14.29%
Success rate
-28.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Outperform | $5 | $1.61 | +210.56% | 1 | Mar 26, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.07 | +769.57% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.26 | +607.96% | 2 | Aug 14, 2024 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | $20 | $2.94 | +580.27% | 1 | Jul 31, 2024 | |
| RVMD Revolution Medicines | Upgrades: Strong Buy | $36 → $48 | $40.50 | +18.52% | 2 | Apr 10, 2024 |
Erasca
Mar 26, 2025
Initiates: Outperform
Price Target: $5
Current: $1.61
Upside: +210.56%
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.07
Upside: +769.57%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.26
Upside: +607.96%
Black Diamond Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: $20
Current: $2.94
Upside: +580.27%
Revolution Medicines
Apr 10, 2024
Upgrades: Strong Buy
Price Target: $36 → $48
Current: $40.50
Upside: +18.52%